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Ceramides increase during obesity and promote
insulin resistance. Ceramides vary in acyl-chain
lengths from C14:0 to C30:0 and are synthesized by
six ceramide synthase enzymes (CerS1–6). It remains
unresolved whether obesity-associated alterations of
specific CerSs and their defined acyl-chain length ce-
ramides contribute to the manifestation of metabolic
diseases. Here we reveal that CERS6 mRNA expres-
sion and C16:0 ceramides are elevated in adipose tis-
sue of obese humans, and increased CERS6 expres-
sion correlates with insulin resistance. Conversely,
CerS6-deficient (CerS6D/D) mice exhibit reduced
C16:0 ceramides and are protected from high-fat-
diet-induced obesity and glucose intolerance. CerS6
deletion increases energy expenditure and improves
glucose tolerance, not only in CerS6D/D mice, but
also in brown adipose tissue- (CerS6DBAT) and liver-
specific (CerS6DLIVER) CerS6 knockout mice. CerS6
deficiency increases lipid utilization in BAT and liver.
These experiments highlight CerS6 inhibition as a
specific approach for the treatment of obesity and
type 2 diabetes mellitus, circumventing the side ef-
fects of global ceramide synthesis inhibition.
INTRODUCTION
Ceramides are linked to obesity-associated metabolic dysfunc-
tion; however, the precisemechanism(s) of action remains poorly
defined (Adams et al., 2004; Holland et al., 2007, 2011; Kolak
et al., 2007). Pharmacological and genetic interventions that
prevent de novo ceramide synthesis ameliorate many critical
features of obesity-related diseases such as insulin resistance,678 Cell Metabolism 20, 678–686, October 7, 2014 ª2014 Elsevier Inatherosclerosis, and cardiomyopathy (Holland and Summers,
2008). Furthermore, it has been demonstrated that the potent
antidiabetic actions of the adipokine, adiponectin, are partly
attributed to adiponectin receptor-associated ceramidase activ-
ity, and consequent ceramide catabolism (Holland et al., 2011;
Okada-Iwabu et al., 2013; Yamauchi et al., 2007). However,
complete inhibition of sphingolipid and/or ceramide synthesis
disrupts many cellular homeostatic and regulatory signaling
pathways; therefore, targeting global de novo ceramide synthe-
sis for the treatment of these diseases poses considerable risk of
adverse effects (Holland et al., 2007).
Ceramidesareat thecenterof sphingolipidmetabolism,andare
formedby theN-acylation of a sphingoid long-chain base. This re-
action is regulated by individual (dihydro) ceramide synthases
(CerSs), which are responsible for the generation of different
acyl-chain ceramides (C14:0–C30:0) (Levy and Futerman, 2010).
The recent generation of CerS-deficient mice has demonstrated
that altering ceramide acyl-chain lengths via the manipulation of
CerSs can have a broad range of functional and tissue-specific ef-
fects (Ginkel et al., 2012; Jennemann et al., 2012; Pewzner-Jung
et al., 2010). For instance, CerS1-derived C18:0 ceramides are
essential for cerebellar development, whereas CerS2-derived
C22:0–24:0 ceramides regulate hepatic function, andCerS3-depen-
dent > C24:0 ceramides are crucial for maintaining skin barrier
function (Ginkel et al., 2012; Jennemann et al., 2012; Pewzner-
Jung et al., 2010). Thus, identifying the specific CerSs and conse-
quently their derived acyl-chain ceramides that contribute to the
development of obesity-associated insulin resistance may point
toward specific therapeutic strategies for this common disease.
RESULTS AND DISCUSSION
CERS6 Expression Is Increased in Adipose Tissue
of Obese Humans
Ceramide levels in the white adipose tissue (WAT), the skeletal
muscle, and the liver are often elevated in obese humans and ro-
dentmodels of obesity (Adams et al., 2004; Kotronen et al., 2010;c.
Figure 1. Expression of Ceramide Synthase
6 Is Positively Correlated with BMI
(A) Correlation between human ceramide synthase
1–6 (CERS1–6) gene expression and body mass in-
dex (BMI) in the visceral white adipose tissue (WAT)
of human subjects (n = 439) normalized to hypo-
xanthine phosphoribosyltransferase 1 (HPRT1).
(B) Acyl-chain ceramides in visceral WAT of lean
and obese subjects (n = 10/group).
(C) Gonadal WAT mRNA expression of CerSs
in normal (ND)- and high-fat diet (HFD)-fed mice
(n = 7 versus 8).
(D) Acyl-chain ceramides in the gonadal WAT of
ND and HFD mice (n = 8/group). Values are ex-
pressed as mean ± SEM; *p < 0.05, **p < 0.01,
***p < 0.001 versus lean (B) or ND (C and D) as
determined by unpaired Student’s t test; r,
Spearman’s correlation coefficient. See also Fig-
ure S1 and Table S1.
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cific acyl-chain ceramides and expression profiling of the
different CerSs in metabolically relevant tissues in obesity has
not yet been conducted. Initially we sought to identify which
CERSs and acyl-chain ceramides were altered in obese human
subjects. Gene expression of CERS1, 2, 4, 5, and 6 was deter-
mined in both visceral and subcutaneous WAT of 439 human
subjects across a broad spectrum of body mass indices
(BMIs). Only CERS6 expression positively correlated with BMI,
body fat content, and hyperglycemia, and negatively correlated
with glucose infusion rate during euglycemic-hyperinsulinemic
clamps (Figures 1A and S1A available online; Table S1). The pos-
itive correlation ofCERS6mRNA expression inWATwith obesity
and insulin resistance suggested that acyl-chain ceramide pro-
files could differ between lean and obese subjects. Indeed, in a
smaller subcohort of 10 lean (BMI < 25 kg/m2) versus 10 obese
(BMI > 30 kg/m2) subjects, C14:0–18:1 and C22:1 ceramides were
increased (Figure 1B). Acyl-chain sphingomyelins, which are
derived directly from ceramide, were also largely elevated in
the obese, compared to lean, subjects (Figure S1B).
Similarly, mice fed a high-fat diet (HFD) showed increased
CerS6 and 1 expression, and correspondingly, C16:0 and C18:0
ceramides were significantly elevated (Figures 1C and 1D); how-
ever, sphingomyelin levels were not increased (Figure S1C). This
indicates that upregulation of CerS6 expression and consequent
increases in specific acyl-chain ceramides could represent a
conserved phenomenon that contributes to both murine and hu-
man obesity; however, we cannot rule out that alterations in other
complex sphingolipids could also contribute. Nonetheless, we
proposed that disrupting individual CerSs could help to deter-
mine if a specific CerS(s) indeed plays a causal role in obesity
development and associated negativemetabolic consequences.
Herein we have utilized the specificity of the CerS6 enzyme to
selectively modulate the generation of C16:0 ceramides.
Ablation of CerS6 Protects from DIO and Glucose
Intolerance
To elucidate the specific role of CerS6-dependent ceramide
synthesis during obesity development, conventional CerS6Cellknockout mice (CerS6D/D) were generated via Cre-recombi-
nase-mediated deletion of exon 4 in theCerS6 gene, in the germ-
line, that induced a frameshift and prevented translation of the
highly conserved, catalytic longevity assurance domain (LAG1)
(Figures S2A and S2B). CerS6D/D mice challenged with a HFD
exhibited reduced C16:0 ceramides in WAT, brown adipose tis-
sue (BAT), and liver, but not in skeletal muscle (Figures 2A–2D).
Strikingly, CerS6D/D mice were protected from diet-induced
obesity (DIO), as evidenced by reduced body weight, decreased
body fat content, reduced adipocyte size, and lower serum leptin
concentrations compared to Control littermates (Figures 2E–2H).
Similarly, CerS6 deletion protected from macrophage infiltration
and activation of proinflammatory gene expression in WAT of
obese CerS6D/D mice (Figures 2I, 2J, and S2C). Indirect calori-
metric analysis revealed that prevention of DIO might be attrib-
uted to an increased rate of energy expenditure (Figure 2K), as
locomotor activity and food consumption were not different
between CerS6D/D and Control mice (Figures S2D and S2E).
While total ceramide accumulation can contribute to insulin
resistance in glucoregulatory tissues (Holland et al., 2007; Kotro-
nen et al., 2010), it is still not known which CerSs are instigating
these effects. As C16:0 ceramides have been primarily implicated
in the induction of insulin resistance in skeletal muscle, and
C16:0–18:0 ceramides have been linked to insulin resistance in the
liver (Chavez and Summers, 2012), we investigated whether the
deletion of CerS6 could improve whole-body glucose meta-
bolism. Indeed, HFD-fedCerS6D/Dmice had significantly reduced
serum insulin concentrations as well as improved glucose toler-
ance and insulin sensitivity compared to Control littermates (Fig-
ures2L–2N). These improvements inglucose toleranceand insulin
sensitivity were also observed in NCD-fed CerS6D/D mice whose
body weight was only marginally lower than Controls (Figures
S2F–S2H). Moreover, insulin-stimulated phosphorylation of pro-
tein kinase B/Akt, and its downstream target glycogen synthase
kinase 3b (GSK3b) was improved in the liver, but not in skeletal
muscle of HFD-fed CerS6D/D mice (Figures 2O and 2P). Collec-
tively, the ablation of CerS6 prevented DIO and glucose intoler-
ance as well as obesity-associated WAT inflammation and
improved insulin action in the livers of obese CerS6D/Dmice.Metabolism 20, 678–686, October 7, 2014 ª2014 Elsevier Inc. 679
Figure 2. CerS6 Deletion Protects from Diet-Induced Obesity and Improves Glucose Tolerance
(A–P) Analysis of high-fat diet (HFD)-fed CerS6D/D mice and Control littermates.
(A–D) Acyl-chain ceramides in the (A) gonadal white adipose tissue (WAT; n = 5/group), (B) brown adipose tissue (BAT; n = 5/group), (C) liver (n = 3/group), and (D)
skeletal muscle (n = 6/group).
(E) Body weight (n = 12/group) and (F) percent body fat (n = 14/group).
(G) Representative images (scale bar, 100 mm) and quantification of adipocyte area in WAT (n = 3/group).
(H) Serum leptin (n = 6/group).
(I) mRNA expression of inflammatory markers in gonadal WAT (n = 7/group).
(J) Representative images (scale bar, 100 mm) and quantification of MAC2-positive cells in gonadal WAT (n = 6/group).
(K) Energy expenditure relative to lean body mass (n = 14 versus 29).
(L) Serum insulin (n = 8 versus 18).
(legend continued on next page)
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Cells Fails to Protect from Obesity-Associated Glucose
Intolerance
Next, we aimed to address in which tissues CerS6 acts to pro-
mote DIO and glucose intolerance. De novo synthesis of C16:0
ceramides in macrophages has been shown to contribute to in-
flammasome activation and is suggested to be a key component
of the signaling networks that connect lipid oversupply to inflam-
matory pathways and insulin resistance (Holland and Summers,
2008; Mitsutake et al., 2012; Schilling et al., 2013). Since
CerS6D/D mice had less WAT proinflammatory macrophage infil-
tration, we sought to determine if myeloid cell-specific CerS6
deletion (CerS6DMYEL) mice could improve the WAT inflammatory
milieu and consequently prevent DIO and/or improve insulin
sensitivity. To this end we crossed CerS6loxP/loxP mice with mice
expressing Cre recombinase under the control of the lysozyme
2 gene (Lyz2) promoter/enhancer elements (LysMCre+/).
Breeding CerS6loxP/loxPLysMCre/ mice with CerS6loxP/loxP
LysMCre+/ mice produced mice with myeloid-specific CerS6
deletion and littermate Controls (denoted as CerS6DMYEL and
Control, respectively). Despite reduced CerS6 expression and
reduced C16:0 ceramides in macrophages, HFD-fed CerS6
DMYEL
mice showed neither differences in body weight and adiposity,
nor any improvements in glucosemetabolism, compared to Con-
trol littermates (Figures S2I–S2P). Moreover, the expression of
genes important and indicative of inflammatory and/or metabolic
signaling in the WAT remained largely unchanged in these ani-
mals (Figure S2Q). These findings exclude the involvement of
CerS6 in myeloid lineage-derived cells to alter whole-body
glucose metabolism and indicate that the prevention of WAT
inflammation in CerS6D/D mice occurs secondary to the preven-
tion of obesity of conventional CerS6-deficient mice.
CerS6 Acts in BAT to Promote Adiposity and
Glucose Intolerance
BAT oxidizes glucose and lipids primarily to produce energy that
is dissipated as heat, and as such, is a highly active metabolic
tissue (Bartelt et al., 2011). De novo ceramide synthesis has
been shown to interfere with the ability of brown adipocytes to
take up glucose (Ferna´ndez-Veledo et al., 2006), indicating that
increased CerS expression and activity could negatively regulate
BAT energy metabolism. Since increased BAT activity is associ-
ated with increased energy expenditure (Bartelt et al., 2011), we
sought to determine if ablation of CerS6 improved BAT function.
Morphological analysis revealed a clear reduction in lipid droplet
volume in BAT of HFD-fedCerS6D/Dmice (Figure 3A). Stimulated
triacylglycerol (TAG) release from ex vivo BAT sections of
CerS6D/D mice was greater than that of Controls, suggestive of
increased lipolysis in this tissue (Figure 3B). BAT mRNA analysis
revealed significant increases in the expression of peroxisome
proliferator-activated receptor gamma coactivator 1 alpha
(Pparg1ca), nuclear respiratory factor 1 (Nrf1), and mitochondrial
transcription factor A (Tfam) in CerS6D/D mice (Figure 3C). How-
ever, maximal respiratory chain enzymes’ capacities inCerS6D/D(M) Glucose and (N) insulin tolerance tests (n = 9 versus 14).
(O and P) Representative immunoblots and quantifications of phosphorylated an
muscle of insulin-stimulated (/+) mice (n = 6/group). Values are expressed as m
unpaired Student’s t test (A–D, F–I, L, O, P) or two-way ANOVA (E, K, M, N). See
CellBAT did not increase (Figure S3A). In agreement with the
absence of increased mitochondrial biogenesis upon CerS6
deletion, the maximal oxygen consumption rate assessed
upon providing glycolytic substrates did not differ between the
BAT of Control and CerS6D/D mice (Figure 3D). Interestingly,
there was a significant elevation in mitochondrial b-oxidative
capacity in isolated brown adipocytes from CerS6D/D mice
compared to Controls (Figure 3E). Taken together, these findings
suggest that deletion of CerS6 reduces lipid accumulation and
improves BAT function through increased mitochondrial
b-oxidative capacity.
To determine if increased BAT lipid oxidative capacity in
CerS6D/D mice contributed to increasing energy expenditure,
therefore protecting CerS6D/D mice from DIO, we deleted
CerS6 specifically in the brown adipocytes of mice. To this
end, we engineered a bacterial artificial chromosome to express
the Cre recombinase specifically in this tissue under control of
the uncoupling protein (Ucp)-1 promoter, and which, upon injec-
tion in fertilized oocytes, yielded Ucp1Cre-transgenic mice (Fig-
ures S3B and S3C). CrossingUcp1Cremice with mice carrying a
loxP-flanked CerS6 allele yielded CerS6flox/floxUcp1Cre/+, i.e.,
CerS6DBAT mice. Despite a modest deletion efficiency of
50%, which was highly restricted to BAT (Figure S3D), HFD-
fed CerS6DBAT mice exhibited reduced adiposity and increased
energy expenditure despite no gross body weight differences
(Figures 3F–3H). Similar to what was observed in conventional
CerS6D/D mice, isolated brown adipocytes from CerS6DBAT
mice showed unaltered utilization of glycolytic substrates, but
increased mitochondrial b-oxidative capacity (Figures 3I and
3J). CerS6DBAT mice also demonstrated a modest improvement
in glucose tolerance, but not insulin sensitivity (Figures 3K and
3L). While the partial deletion of CerS6 specifically in the BAT
expectedly did not fully recapitulate the profound metabolic
improvements observed in CerS6D/D mice, these experiments
illustrate that CerS6 may play a significant role in regulating
BAT mitochondrial b-oxidative capacity to increase energy
expenditure and improve systemic glucose homeostasis.
Hepatic CerS6 Action Contributes to Diet-Induced
Weight Gain and Glucose Intolerance
The liver is also a major site of lipid synthesis, storage, utilization,
and export, as well as glucose metabolism. Deletion of key en-
zymes in the lipolysis, esterification, and fatty acid oxidation
pathways can lead to dysregulation of lipid and glucose homeo-
stasis in a variety of peripheral tissues (Girousse and Langin,
2012). Analysis of CerS expression in the livers of HFD mice
demonstrated that only CerS6was upregulated with DIO, similar
to what was observed in the adipose tissue of obese human sub-
jects (Figure S4A). This coincided with increased C14:0, C16:0,
C18:0, C20:0, and C24:1 acyl-chain ceramides (Figure S4B), while
in the livers of CerS6D/Dmice, only C14:0 and C16:0 acyl-chain ce-
ramides were selectively reduced (Figure 2C). Given the effect of
CerS6 deficiency on b-oxidative capacity in BAT, we aimed to
elucidate whether the deletion of CerS6 could also improved total Akt and glycogen synthase kinase 3 (GSK3) in (O) liver and (P) skeletal
ean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 versus Control as determined by
also Figure S2.
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Figure 3. Deletion of CerS6 Increases b-Oxidative Capacity in Brown Adipocytes
Analysis of high-fat diet (HFD)-fed (A–E) CerS6D/D mice, (F–L) CerS6DBAT mice, and Control littermates.
(A) Hematoxylin and eosin stain of brown adipose tissue (BAT) sections (large scale bars, 100 mm; short scale bars, 10 mm) from HFD-fed Control and CerS6D/D
mice.
(B) Triacylglycerol (TAG) release from BAT ex vivo (n = 8/group).
(C) mRNA expression of mitochondrial BAT functional regulators (n = 6/group).
(D and E) Mitochondrial oxygen consumption in response to (D) glucose-3-phosphate (G3P) and (E) palmitoylcarnitine (PalCarnitine) in brown adipocytes (n =
13/group).
(F) Body weight (n = 18/group), (G) percent body fat (n = 14/group), and (H) energy expenditure (n = 12/group) relative to lean body mass of HFD-fed Control
andCerS6DBAT mice. Mitochondrial oxygen consumption in response to (I) G3P and (J) PalCarnitine in brown adipocytes fromHFD-fed Control andCerS6
DBAT mice
(n = 4/group). (K) Glucose (6 hr fast, n = 10 versus 12) and (L) insulin (1 U/kg, n = 20 versus 16) tolerance tests. Values are expressed as mean ± SEM; *p < 0.05,
**p < 0.01 versus Control as determined by unpaired Student’s t test (B, C, E, G, J) or two-way ANOVA (H, K, L). See also Figure S3.
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Figure 4. Hepatic Deletion of CerS6 Increases Palmitate Oxidation and Improves Glucose Metabolism
Analysis of high-fat diet (HFD)-fed (A–D) CerS6D/D mice, (E–I) CerS6DLIVER mice, and Control littermates.
(A) mRNA expression (n = 8/group) and (B) immunoblots and quantifications of functional metabolic regulators in the liver (n = 7/group).
(C) Palmitate oxidation and (D) percentage complete palmitate oxidation in primary hepatocytes (n = 8 versus 10 mice).
(E) Hepatic ceramide (n = 7 versus 5) and (F) body weight of HFD-fed Control and CerS6DLIVER mice (n = 5 versus 7).
(G) Glucose (n = 12 versus 18) and (H) insulin (1 U/kg) tolerance tests (n = 7/group).
(I) Representative immunoblots and quantifications of phosphorylated and total Akt in primary hepatocytes, pretreated (/+) with 0.5 mM palmitate for 6 hr, then
insulin stimulated for 15 min (/+); arrows indicate 55 kDa ladder (n = 6/group). Values are expressed as mean ± SEM; *p < 0.05, **p < 0.01 versus Control as
determined by unpaired Student’s t test (A–E) or two-way ANOVA (F–I). See also Figure S4.
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and protein expression of key regulators of hepatic lipid meta-
bolism in livers of Control and CerS6D/D mice. This analysis re-
vealed a reduction of either mRNA and/or protein expression
of the transcription factor peroxisome proliferator-activated re-
ceptor gamma (Pparg) and its transcriptional targets, cluster ofCelldifferentiation 36 (Cd36), fatty acid binding protein 4 (Fabp4),
and stearoyl-CoA desaturase 1 (Scd1) in the livers of CerS6D/D
mice independent of altered 50 AMP-activated protein kinase
phosphorylation (AMPK) (Figures 4A and 4B).
As PPARg target genes control the uptake of lipids, and
PPARg has been suggested to regulate the storage of lipids inMetabolism 20, 678–686, October 7, 2014 ª2014 Elsevier Inc. 683
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mary hepatocytes isolated from HFD-fed Control and CerS6D/D
mice. The deletion of CerS6 resulted in both more efficient and
increased rates of palmitate oxidation (Figures 4C and 4D). To
investigate potential mechanisms underlying these effects, we
measured levels of fibroblast growth factor 21 (FGF21), which,
through PPARa, increases hepatic lipid metabolism, and can
also alter ceramide metabolism in an adiponectin-dependent
manner (Holland et al., 2013). However, the mRNA expression
of Fgf21 in the liver was reduced, as were circulating levels of
FGF21 in CerS6D/D mice (Figures 4A and S4C). Neither were
there changes in PPARa, nor circulating high-molecular-weight
adiponectin (Figures 4A, 4B, S4D, and S4E), which indicates
that the elevated lipid oxidation in the livers ofCerS6D/Dmice oc-
curs independently of FGF21 and adiponectin. Collectively,
these experiments indicate that ablation of CerS6 and thus abro-
gating obesity-induced increases in CerS6 promotes b-oxidation
both in the BAT and liver.
To further elucidate whether hepatic CerS6 deficiency
also contributes to the improved metabolism observed in
CerS6D/D mice, we generated liver-specific CerS6-deficient
mice (CerS6DLIVER). To this end, we crossed CerS6loxP/loxP mice
with mice expressing Cre recombinase under the control of the
mouse albumin enhancer and promoter and the mouse alpha-
fetoprotein enhancers (AlfpCre mice) (Kellendonk et al., 2000).
Breeding CerS6loxP/loxPAlfpCre/ mice with CerS6loxP/loxP
AlfpCre+/ mice produced mice with hepatocyte-specific CerS6
deletion and littermate Controls (denoted as CerS6DLIVER and
Control, respectively). CerS6DLIVER mice showed a selective
reduction in both hepatic C16:0 ceramides and dihydroceramides
compared to Controls (Figures 4E, S4F, and S4G). While obese
CerS6DLIVER mice were only subtly protected from HFD-induced
body weight gain (Figure 4F), the deletion of hepatic CerS6 led to
significantly improved glucose tolerance, but not insulin sensi-
tivity, compared to Control littermates (Figures 4G and 4H).
Furthermore, primary hepatocytes isolated from CerS6DLIVER
mice were protected from palmitate-induced reductions in insu-
lin-stimulated Akt phosphorylation (Figure 4I), indicating that
CerS6 is obligate for saturated fatty acid-induced hepatic insulin
resistance. Taken together, our experiments highlight a specific
causal role for CerS6, and consequently the generation of C16:0
ceramides, in the development of obesity and glucose intoler-
ance in mice and humans.
Conclusions
Herein we report a strong correlation, exclusively between
CerS6 expression in visceral and subcutaneousWAT of humans,
with BMI and insulin resistance. Furthermore, we demonstrate
that the main product of CerS6, C16:0 ceramide, is also elevated
in the visceral WAT of obese humans, as well as in WAT and liver
of HFD-fed mice. These data are consistent with others who
recently showed that C16:0 ceramide in human subcutaneous ad-
ipose tissue correlates with HOMA-IR (B1achnio-Zabielska et al.,
2012). In conjunction with the clear protection from obesity and
improvement of insulin resistance and glucose tolerance in
CerS6-deficient mice, these experiments indicate the specific
importance of CerS6-derived C16:0 ceramide in the pathogenesis
of obesity and insulin resistance. Consistent with this notion,
mice that are haploinsufficient for CerS2, thus resulting in a684 Cell Metabolism 20, 678–686, October 7, 2014 ª2014 Elsevier Incompensatory upregulation of C16:0 ceramides, develop hepa-
tosteatosis and insulin resistance (Raichur et al., 2014). While
previous studies had revealed that either chemical inhibition or
genetic manipulation of ceramide accumulation can alleviate in-
sulin resistance both independent of and parallel with reduced
adiposity (Boon et al., 2013; Holland et al., 2007; Turinsky
et al., 1990; Ussher et al., 2010; Yang et al., 2009; Zhang et al.,
2012), we demonstrate a critical role for distinct acyl-chain
length specificity of ceramides in the development of both
obesity and insulin resistance.
The first evidence of distinct and specific functions of CerS
enzymes and their ceramide products stems from work in
C. elegans (Menuz et al., 2009). Here the deletion of the CerS ho-
molog hyl-1 (catalyzing the synthesis of C24:0–26:0 ceramides)
decreased sensitivity to hypoxia, while deletion of hyl-2 (cata-
lyzing the synthesis of C20:0–22:0 ceramides) increased hypoxia
sensitivity (Menuz et al., 2009) in the absence of alterations in to-
tal ceramide levels. In conjunction with the generation of other
specific CerS knockout mice (Ginkel et al., 2012; Jennemann
et al., 2012; Pewzner-Jung et al., 2010), we further confirm the
notion that CerSs and consequently their acyl-chain ceramide
products have unique biological functions.
Specifically, we have identified CerS6 as a negative regulator
of b-oxidative capacity in the BAT and the liver. These effects, in
contrast to Zigdon et al. (Zigdon et al., 2013), appear to be inde-
pendent of increases in respiratory chain capacity. While we
cannot exclude that CerS6 may be acting in other areas or dis-
count the potential of developmental contributions of CerS6 defi-
ciency, the generation of mice with specific deletion of CerS6 in
the BAT and liver clearly demonstrates thatCerS6 alters lipid uti-
lization in these tissues.
In conclusion, we have identified a role for CerS6 to modulate
b-oxidation in BAT and liver to impair whole-body energy and
glucose homeostasis in obesity. Hence, we provide evidence
that a targeted pharmacological inhibition ofCerS6 could enable
the generation of specific therapeutic approaches to combat
obesity and type 2 diabetesmellitus and circumvent the potential
adverse effects of blocking global ceramide synthesis.
EXPERIMENTAL PROCEDURES
Extensive experimental details can be found in Supplemental Experimental
Procedures.
Human Subjects
The study was approved by the local ethics committee (Reg. No. 031-2006
and 017-12-23012012), and the participants gave their informed written
consent.
Animal Care
All animal procedures were conducted in compliance with protocols
approved by local government authorities (Bezirksregierung Ko¨ln) and were
in accordance with NIH guidelines. Mice were allowed ad libitum access to
food and water and maintained in a facility with a 12 hr light/dark cycle at
22C–24C.
Mouse Analysis
All experimental procedures were conducted using male mice as described
below. Mice were placed on a HFD at weaning (i.e., 3 weeks of age). Body
weight was assessed weekly from 3 to 15 weeks of age. ITT was conducted
at 11 weeks, and GTT was conducted at 12 weeks. Between 15 and 18 weeks,
mice were placed in metabolic chambers for calorimetric analysis. Atc.
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tion at 20 weeks of age.
Lipid Analysis
Sphingolipid levels were determined by liquid chromatography coupled to
electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). Tissues
were homogenized in water (10 mg of tissue per 100 ml) using the Precellys 24
Homogenizator (PEQLAB). Lipid extraction and LC-ESI-MS/MS analysis were
performed as previously described (Schwamb et al., 2012). Samples were
measured in duplicate.
Statistical Analysis
Data were analyzed for statistical significance using either Spearman’s corre-
lation coefficient, a two-way ANOVA with or without repeated measures, Bon-
ferroni post hoc tests, or a two-tailed unpaired Student’s t test as appropriate.
p values less than 0.05 were considered statistically significant. All quantitative
data are shown as the mean ± SEM.
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